Literature DB >> 20187238

Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.

Manolo Carta1, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklund.   

Abstract

Recent studies in animal models of Parkinson's disease (PD) have provided evidence that dopamine released from spared serotonin afferents can act as a trigger of dyskinetic movements induced by repetitive, low doses of levodopa. Serotonin neurons have the capacity to store and release dopamine synthesized from systemically administered levodopa. However, because of the lack of any autoregulatory feedback control, dopamine released from serotonin terminals results in excessive swings in extracellular dopamine levels after peripheral administration of levodopa. Such "dysregulated" release of levodopa-derived dopamine is likely to be responsible for the appearance of the abnormal movements in levodopa-primed animals. This mechanism may also play a role in the development of graft-induced dyskinesias in patients that receive fetal neuron transplants, possibly due to the inclusion of serotonin neurons in the grafted ventral midbrain tissue, which contribute to maintain dopamine receptors of the denervated striatum in a supersensitive state.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187238     DOI: 10.1002/mds.22792

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

Review 1.  Anatomy, Physiology, and Clinical Syndromes of the Basal Ganglia: A Brief Review.

Authors:  Arash Fazl; Jori Fleisher
Journal:  Semin Pediatr Neurol       Date:  2017-12-27       Impact factor: 1.636

2.  Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Authors:  Daniella Rylander; Vincenza Bagetta; Valentina Pendolino; Elisa Zianni; Shane Grealish; Fabrizio Gardoni; Monica Di Luca; Paolo Calabresi; M Angela Cenci; Barbara Picconi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

3.  Functional neuroanatomy of the basal ganglia.

Authors:  José L Lanciego; Natasha Luquin; José A Obeso
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

5.  Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Authors:  Celia Painous; Andres Perissinotti; Maria J Martí
Journal:  Ann Transl Med       Date:  2019-12

6.  Dampening of Serotonergic System through 5HT1A Receptors is a Promising Target for Treatment of Levodopa Induced Motor Problems.

Authors:  Javad Mahmoudi; Mehdi Farhoudi; Siamak Reyhani-Rad; Saeed Sadigh-Eteghad
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 7.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

Review 8.  Electrochemistry at the Synapse.

Authors:  Mimi Shin; Ying Wang; Jason R Borgus; B Jill Venton
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2019-02-01       Impact factor: 10.745

Review 9.  Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.

Authors:  Elisabetta Tronci; Veronica Francardo
Journal:  J Neural Transm (Vienna)       Date:  2017-12-14       Impact factor: 3.575

Review 10.  Emerging therapies in Parkinson disease - repurposed drugs and new approaches.

Authors:  Ahmad Elkouzi; Vinata Vedam-Mai; Robert S Eisinger; Michael S Okun
Journal:  Nat Rev Neurol       Date:  2019-04       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.